When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. | Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails.

Rome’s pipeline is built on twin franchise, one composed of reverse transcriptase inhibitors and another pursuing tumor ...

UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase ...

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that ...

Medtronic has announced plans to double the footprint of its London office, focused on developing artificial intelligence and ...

Tuesday morning, Seres confirmed that one of these actions would involve reducing its workforce by 25%. Employees who are ...

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple ...

Glooko is looking to expand its diabetes treatment platforms to the inpatient setting, with a plan to acquire Monarch Medical ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate ...

The New York Stock Exchange helped ring in this year’s Fierce 15 by honoring the winners on the trading floor Monday morning.

Pfizer has thrown money at its obesity R&D problem. Having seen its internal assets flounder, the Big Pharma has struck a ...